To the Editor: With much interest we read the paper by Carvalho et al, which demonstrated that including triacylglycerol-rich lipoproteins (TRL) particle diameter in a risk prediction model improved the risk prediction of incident type 2 diabetes after a mean 3.7 years of follow-up in the Estudo Longitudinal de Saúde do Adulto (Brazilian Longitudinal Study of Adult Health; ELSA-Brasil) cohort, particularly in participants with lower HbA1c levels [1]. TRL particle diameter is a lipoprotein metric that is likely to undergo changes early in the course of the pathophysiological processes that lead to the development of type 2 diabetes, even before plasma glucose abnormalities are established [2]. We have reported that, in the Prevention of Renal and Vascular End-Stage Disease (PREVEND) cohort, TRL size was positively associated, whereas LDL size was inversely associated, with incident type 2 diabetes [3]. Notably, in the same population, we also found that HDL particle size and the concentration of large HDL particles were both inversely associated with incident type 2 diabetes [4], consistent with a protective effect of HDL on beta cell function [5]. Hence, it is plausible that including lipoprotein diameter markers (such as LDL and HDL size) other than TRL size alone in risk prediction models may improve the prediction of incident type 2 diabetes.

Here, we present novel data from our recent studies [3, 4], aiming to investigate whether, and to what extent, the size of TRL, LDL and HDL particles, and the ratios and combinations of these lipoprotein particle sizes, are independently associated with incident type 2 diabetes. Furthermore, we question whether the addition of LDL and/or HDL size to risk prediction models improves type 2 diabetes risk prediction over the inclusion of TRL size alone.

After exclusion of participants with missing data, a total of 4818 participants of the PREVEND study without type 2 diabetes at baseline were included in this study [3, 4]. After a median follow-up of 7.3 years, 263 participants had developed type 2 diabetes, which was determined if one or more of...
the following criteria were met: (1) fasting plasma glucose (FPG) ≥7.0 mmol/l; (2) random sample plasma glucose ≥11.1 mmol/l; (3) self-report of a physician diagnosis of type 2 diabetes; and (4) initiation of glucose-lowering medication use, retrieved from a central pharmacy registry. The protocol for the PREVEND study was approved by the local ethics committee of the University Medical Center Groningen (approval number: MEC96/01/022).

After an overnight fast, EDTA anti-coagulated plasma samples were obtained, and lipoprotein variables were measured by NMR LipoProfile testing at Labcorp (Morrisville, NC, USA). Lipoprotein variables were reported using an optimised version of the NMR LipoProfile test (LP4 algorithm) [3, 4, 6]. Mean TRL, LDL and HDL sizes were calculated using the weighted mean derived from the sum of the diameters of each subfraction. This contrasts with the ELSA-Brasil report, which relied on the earlier LP3 algorithm employed by the same laboratory; one important difference is that intermediate density lipoproteins are categorised as an LDL subtraction with the LP3 algorithm and as a VLDL subtraction with the LP4 algorithm. In view of the reciprocal relationship between TRL and HDL sizes, as well as between TRL and LDL sizes, lipoprotein particle size ratios were calculated by dividing the size of one lipoprotein fraction by the size of another lipoprotein fraction. We also calculated the combined TRL and HDL size variable, which was estimated by the combined predictive probability of TRL and HDL size related to incident type 2 diabetes using logistic regression analyses.

Crude and multivariable Cox proportional hazards regression analyses were performed to examine the associations between each lipoprotein particle size variable and incident type 2 diabetes. We estimated changes in the risk of developing diabetes with inclusion of TRL, LDL and HDL size, their ratios, and the combined TRL and HDL size variable using the Framingham Offspring (FOS) risk score, a traditional type 2 diabetes risk assessment tool that takes into account age, sex, family history of type 2 diabetes, BMI, BP and FPG, as a base model [7]. Harrell’s C-statistics were calculated with and without the inclusion of each lipoprotein particle size variable in the models, and differences were tested. Additionally, improvement of diabetes prediction was examined in terms of the net reclassification index (NRI) and integrated discrimination improvement (IDI) [8].

Higher values of TRL size, as well as higher ratios of TRL/LDL size, TRL/HDL size, and LDL/HDL size, and the combined TRL and HDL size estimate, were associated with increased risk of type 2 diabetes, whereas both LDL and HDL size were associated with a lower risk of type 2 diabetes in the crude analysis (Table 1). Except for the LDL/HDL size ratio, the associations remained significant for all of the lipid variables in multivariable-adjusted Cox regression models after adjustment for multiple type 2 diabetes risk factors, including high alcohol intake (>3 units/day), BMI, lipid-lowering medication, anti-hypertensive medication, family history of diabetes, FPG and fasting plasma insulin. The association of TRL size with incident type 2 diabetes was similar to that of the TRL/HDL and the TRL/LDL size ratios, and the combined TRL and HDL size estimate (Table 1). Except for the LDL/HDL size ratio, IDI and NRI estimates were greater after the addition of each of the lipoprotein size indices to the FOS risk score (Table 2).

In summary, these findings in a large population-based cohort corroborate the findings of Carvalho et al about the association between TRL size and incident type 2 diabetes [1]. However, we propose that although TRL, LDL and HDL size are all associated with incident type 2 diabetes after adjustment for relevant potential confounders, the TRL/HDL size ratio, and combined TRL and HDL size estimate seem more robust in improving type 2 diabetes risk prediction. Hence, reporting all major lipoprotein fractions is likely to be useful for the risk prediction of type 2 diabetes development.
| Variable   | TRL size (95% CI) | LDL size (95% CI) | HDL size (95% CI) | TRL/LDL size (95% CI) | TRL/HDL size (95% CI) | LDL/HDL size (95% CI) | Combined TRL and HDL size (95% CI) |
|------------|-------------------|-------------------|-------------------|-----------------------|-----------------------|-----------------------|-----------------------------------|
| Crude      | 1.68 (1.53–1.84)*** | 0.62 (0.57–0.69)*** | 0.50 (0.44–0.58)*** | 1.69 (1.54–1.85)*** | 1.76 (1.61–1.93)*** | 1.44 (1.26–1.63)*** | 1.61 (1.47–1.77)*** |
| Model 1    | 1.65 (1.50–1.82)*** | 0.64 (0.58–0.71)*** | 0.48 (0.41–0.56)*** | 1.66 (1.52–1.83)*** | 1.74 (1.58–1.91)*** | 1.42 (1.23–1.63)*** | 1.59 (1.45–1.75)*** |
| Model 2    | 1.45 (1.30–1.61)*** | 0.75 (0.67–0.84)*** | 0.60 (0.50–0.71)*** | 1.45 (1.31–1.61)*** | 1.51 (1.36–1.68)*** | 1.24 (1.07–1.44)**  | 1.41 (1.27–1.56)**  |
| Model 3    | 1.32 (1.19–1.47)*** | 0.77 (0.69–0.87)*** | 0.64 (0.54–0.77)*** | 1.33 (1.20–1.48)*** | 1.37 (1.23–1.53)*** | 1.17 (1.01–1.35)*   | 1.29 (1.16–1.43)*** |
| Model 4    | 1.26 (1.12–1.41)*** | 0.80 (0.71–0.90)*** | 0.69 (0.58–0.83)*** | 1.27 (1.14–1.43)*** | 1.31 (1.16–1.47)*** | 1.11 (0.96–1.29)    | 1.23 (1.10–1.38)**  |

**Table 1** Association between lipoprotein size variables and risk of type 2 diabetes in 4818 participants of the PREVEND cohort

HR (95% CI) for risk of type 2 diabetes, derived from Cox proportional hazard models and expressed per 1 SD increase in variables.

Model 1, adjusted for sex and age; Model 2, model 1 + high alcohol intake (>3 units/day), BMI, lipid-lowering medication, anti-hypertensive medication and family history of diabetes; Model 3, model 2 + FPG; Model 4, model 3 + fasting plasma insulin.

*p < 0.05; **p < 0.01; ***p < 0.001
### Table 2  Additive value of lipoprotein size for the prediction of type 2 diabetes in 4818 participants of the PREVEND cohort

| Model                          | C-statistics | $p$ value for change in C-statistics | IDI | $p$ value | NRI | $p$ value |
|-------------------------------|--------------|--------------------------------------|-----|-----------|-----|-----------|
| Base model                    | 0.879 (0.859–0.899) | –                                    | –   | –         | –   | –         |
| +TRL size                     | 0.883 (0.863–0.903) | 0.067                                | 0.0119 | 0.0012 | 0.266 | <0.001 |
| +LDL size                     | 0.881 (0.860–0.902) | 0.587                                | 0.0102 | 0.0011 | 0.254 | <0.001 |
| +HDL size                     | 0.883 (0.864–0.903) | 0.170                                | 0.0064 | 0.0103 | 0.295 | <0.001 |
| +TRL/LDL size                 | 0.883 (0.863–0.903) | 0.071                                | 0.0132 | <0.001 | 0.292 | <0.001 |
| +TRL/HDL Size                 | 0.884 (0.864–0.904) | 0.041                                | 0.0142 | <0.001 | 0.327 | <0.001 |
| +LDL/HDL size                 | 0.881(0.861–0.901) | 0.149                                | –0.0005 | 0.6911 | 0.195 | 0.001 |
| +Combined TRL and HDL size    | 0.883 (0.864–0.904) | 0.031                                | 0.0147 | <0.001 | 0.380 | <0.001 |

Base model defined as FOS risk score including age, sex, BMI, family history of diabetes, systolic BP, diastolic BP and FPG

### Data availability
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

### Funding
This project received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 754425. NMR Lipoproteins were measured at Laboratory Corporation of America® Holdings (Labcorp; Morrisville, NC, USA) at no costs.

### Authors’ relationships and activities
MAC and EG are employees of Labcorp. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

### Contribution statement
SS and RPFD conceived and designed the study, participated in the acquisition, analysis and interpretation of data, wrote and critically revised the manuscript. JLFG helped with data analysis and edited the final manuscript. HJLH, EG, MAC, and SJLB participated in analysis and interpretation of data and critically revised the manuscript. All authors have read and approved the final manuscript and have agreed to be accountable for all aspects of the work.

### Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

### References
1. Carvalho LSF, Benseñor IM, Nogueira ACC et al (2021) Increased particle size of triacylglycerol-enriched remnant lipoproteins, but not their plasma concentration or lipid content, augments risk prediction of incident type 2 diabetes. Diabetologia 64(2):385–396. https://doi.org/10.1007/s00125-020-05322-1
2. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM (2010) Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 59(5):1153–1160. https://doi.org/10.2337/db09-1114
3. Sokooti S, Flores-Guerrero JL, Heerspink HJL, Connelly MA, Bakker SJL, Dullaart RPF (2021) Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study. Cardiovasc Diabetol 20(1):1–14. https://doi.org/10.1186/s12933-021-01348-w
4. Sokooti S, Flores-Guerrero JL, Kieneker LM et al (2021) HDL particle subspecies and their association with incident type 2 diabetes: the PREVEND study. J Clin Endocrinol Metab 106(6):1761–1772. https://doi.org/10.1210/clinem/dgab075
5. Drew BG, Rye K-A, Duffy SJ, Barter P, Kingwell BA (2012) The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 8: 237. https://doi.org/10.1038/nrendo.2011.235
6. Matyus SP, Braun PJ, Wolak-Dinsmore J et al (2014) NMR measurement of LDL particle number using the Vantera® clinical analyzer. Clin Biochem 47(16–17):203–210. https://doi.org/10.1016/j.clinbiochem.2014.07.015
7. Wilson PWF, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB (2007) Prediction of incident diabetes mellitus in middle-aged adults: the Framingham offspring study. Arch Intern Med 167(10):1068–1074. https://doi.org/10.1001/archinte.167.10.1068
8. Pencina MJ, Steyerberg EW, D’Agostino RB Sr (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarker. Stat Med 30(1):11–21. https://doi.org/10.1002/sim.4085

### Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.